Pfizer bets big on PD-1xVEGF Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M Tue W Th F 20 May, 2025

LGBTQ+ professionals are instituting change and forging ahead in every sector of the life sciences field — and we’re spotlighting the leaders to watch at our virtual event. Join us in celebration, sign up today.

presented by Does your sup­ply chain hold up un­der pres­sure for high-risk tem­per­a­ture-crit­i­cal ship­ments?

news Bioregnum Endpoints 100 biotech survey: Welcome to the summer of biotech’s discontent Pfizer joins PD-1xVEGF race with $1.25B upfront to Chinese biotech 3SBio Retro Biosciences inks blood disorder deal as Sam Altman-backed biotech seeks $1B in funds

May 29 10:30am ET Optimizing the clinical research workforce - An industry analysis by Parexel sponsored by Parexel Jun 03 11:00am ET Building robust health system partnerships for life sciences sponsored by Advisory Board Jun 18 12:00pm ET Illuminating the CKD patient journey: Clinicogenomic data reshapes research & drug discovery sponsored by Natera

Exploring Japan as a key market for your drug? Get the roadmap — join senior Japanese leaders to hear firsthand on the regulatory and pricing dynamics behind one of the world’s top pharma markets. Sign up now.

endpoints pharma Why Regeneron is buying 23andMe •  Regeneron plans to buy 23andMe for $256M Stelara biosimilars look to gain traction, helped by recent lessons from Humira Boehringer Ingelheim’s late-stage data for lung disease candidate underwhelm some analysts

in case you missed it 1. David Liu, Sam Sternberg unveil new way to insert big genes in human cells 2. Prime Medicine sidelines only clinical program, replaces CEO and lays off some staff 3. Intellia's CRISPR therapy likely causes 'permanent' gene knockdown in ATTR amyloidosis 4. Exclusive: CellCentric collects $120M to treat multiple myeloma with a capsule 5. Apnimed posts first set of Phase 3 sleep apnea results, aims for approval filing in 2026 6. FDA approves Novavax's Covid vaccine after six-week delay, but for a smaller population 7. Denmark’s Economy Contracts, Dragged Down by Lower Pharma Sales